Диссертация (1141138), страница 22
Текст из файла (страница 22)
C. Infections associated with steroid use / N. C. Klein, C. H. Go, B. A.Cunha // Infect. Dis. Clin. North. Am. – 2001. – Vol. 15. – № 2. – P. 423-432.274. Koussidou, T. Onychomycosis in northern Greece during 1994–1998 / T.Koussidou et al. // Mycoses. – 2002. – Vol. 45.
– № 1-2. – P. 29-37.275. Lateur, N. Two hundred ninety-six cases of onychomycosis in children andteenagers: a 10-year laboratory survey / N. Lateur, А. Mortaki, J. Andre //Pediatr. Dermatol. – 2003. – Vol. 20. – № 5. – P. 385-8.276. Leyden, J. J. Interdigital athlets foot: new concepts in pathogenesis / J. J. Leyden,A. M. Kligmann // Postgrad. Med. – 1977. – Vol. 61. – P. 113-116.277. Liebel, F. Anti-inflammatory and anti-itch activity of sertaconazole nitrate / F.Liebel, P.
Lyte, M. Garay et al. // Arch. Dermatol. Res. – 2006. – Vol. 298. – №4. – P. 191-199.278. Lionakis, M. S. Glucocorticoids and invasive fungal infections / M. S. Lionakis,D. P. Kontoyiannis // Lancet. – 2003. – Vol. 362. – P. 1828-1838.141279. Macura, A. B. Nail susceptibility to fungal infections in patients with hypothyroidism and hyperthyroidism / A. B.
Macura, Т. Gasinska, В. Pawlik // Przegl.Lec. – 2005. – Vol. 62. – № 4. – P. 218-221.280. Mahajan, V. K. Cutaneous sporotrichosis in Himachal Pradesh India / V. K.Mahajan, N. L. Sharma, R. C. Sharma et al. // Mycoses. – 2005. – Vol. 48. – P.25-31.281.
Martinez-Roig A. Depmatophytoses in children and adolescents. Epidemiological study in the city of Barselona, Spain / A. Martinez-Roig, I. Torres-Rodriguez// Mykosen. – 1986. – Vol. 24. – № 7. – P. 311-315.282. Mc Aller, R. Fungal infections of the nails in western Australia / R. Mc Aller //Mycopathologia (Den Haag). – 1981. – Vol. 73.
– P. 115-120.283. Mirada, A. Efficacy and tolerability of itraconazole in athletes foot in out patients Spanish population / A. Mirada, J. S. Lopez, M. Arter // JEADV. – 2001.– Vol. 15. – № 2. – P. 116.284. Mistik, S. What defines the quality of patient care in tinea pedis / S. Mistik, A.Ferahbas, A. N. Кос et. al.
// Eur. Acad. Dermatol. Venerol. – 2006. – Vol. 20. –P. 158-165.285. Palacin, C. In vitro activity of sertaconazole / C. Palacin, A. Saeristen, J. A.Ortiz // Arzneim-Forsch. Drug Res. – 1992. – Vol. 42. – № 5a. – P. 699-705.286. Palacin, C. In vitro activity of sertaconazole, fluconazole, ketoconazole,fenticonazole, clotrimazole and itraconazole against pathogenic vaginal yeastisolates / C.
Palacín, C. Tarrago , J. Agut , A. Guglietta // Methods Find. Exp.Clin. Pharmacol. – 2001. – Vol. 23. – P. 61-64.287. Panackal, A. A. Cutaneous fungal 168 infections in the United States: Analysisof the National Ambulatory Medical 169 Care Survey (NAMCS) and NationalHospital Ambulatory Medical Care 170 Survey (NHAMCS), 1995-2004 / A. A.Panackal, E. F. Halpern, A. J. Watson // Int. J. Dermatol. – 2009.
– Vol. 48. – P.704-12.142288. Pandey, A. Isolation and characterization of dermatophytes with tinea infectionsat Gwalior (MP), India / A. Pandey, M. Pandey // Int. J. Pharm. Sci. Invent. –2013. – Vol.2. – P. 5-8.289. Pauw, B. E. Achievements and goals of the EORTC Invasive Fungal InfectionsGroup / B. E.
Pauw, R. Herbrecht, F. Meunier // Eur. J. Cancer. – 2002. – Vol.38. – P. 88-93.290. Pedragosa, R. Therapeutic efficacy and safety of the new antimycoticsertaconazole in the treatment of cutaneous dermatophytosis / R. Pedragosa, B.Gonzdiez, M. Martin et al. // Arzneim-Forsch. Drug Res. – 1992.
– Vol. 42. – №5a. – P. 760-763.291. Perea, S. Prevalence and risk factors of tinea unguium and tinea pedis in thegeneral population in Spain / S. Perea, M. J. Ramos, M. Garau, A. Gonzalez //Journal of clinical microbiology. – 2000. – Vol. 38. – № 9. – P. 3226-30.292. Pfaller, M. Rewview of in vitro activity of sertaconazole nitrate in the treatmentof superficial fungal infections / M. Pfaller, D.
Sutton // Diagn. Microbiol. Infect.Dis. – 2006. – Vol. 56. – № 2. – P. 147-152.293. Piérard, G. E. Treatment and prophylaxis of tinea infections / G. E. Piérard, J. E.Arrese, C. Piérard-Franchimont // Drugs. – 1996. – Vol. 52. – № 2. – P. 209-224.294. Piraccini, B. M. Update on the management of onychomycosis / B.
M. Piraccini,C. G. Gianni // Ital. Dermatol. Venerol. – 2013. – Vol. 148. – № 6. – P. 633-8.295. Purim, K. S. Fungal infection of the feet in soccer players and non-athlete individuals / K. S. Purim, G. P. Bordignon, F. Queiroz-Telles // Rev. Iberoam. Micol.– 2005. – Vol. 22. – № 1. – P. 34-38.296. Ramanan, G. A clinic-mycological study of tinea pedis in North-Eastern India /G. Ramanan, G. Single, P. A. // Kaur Indian J. Dermatol. Venerol. Leprol. –1985. – Vol.
151. – № 1. – P. 40-41.297. Ranaldi, M. G. Dermatophytosis: epidemiological and microbiological. Update /M. G. Ranaldi // J. Amer. Acad. Dermatol. – 2000. – Vol. 43. – P. 120-124.298. Ribotsky, B. M. Sertaconazole nitrate cream 2% for the treatment of tinea pedis/ B. M. Ribotsky // Cutis. – 2009. – Vol. 83. – P. 274-7.143299. Rogers, D. The descriptive epidemiology of tinea pedis in the community / D.Rogers, M.
Kilkenny, R. Marks // Australasian journal of dermatology. – 1996.– Vol. 37. – № 4. – P. 178-184.300. Romano, C. Onychomycosis caused by Alternania spp: in Tuscany, Italy from1985 to 1999 / C. Romano, Е. Paccagnini, М. Difonso // Mycoses. – 2001. – Vol.44. – № 3-4. – P.
73-76.301. Roseeuw, D. Achilles foot screening project: preliminary results of patientsscreened by dermatologists / D. J. Roseeuw // Europ. Acad. Dermatol. Venereol.– 1999. – Vol. 12. – № 1. – P. 6-9.302. Rotta, I. Efficacy of topical antifungals in the treatment of dermatophytosis: amixed-treatment comparison meta-analysis involving 14 treatments / I. Rotta, P.K.
Ziegelmann, M. F. Otuki et. al. // JAMA Dermatol. – 2013. – Vol. 149. – №3. – P. 341-9.303. Roujeau, J. C. Risk factors for erysipelas of the leg (cellulitis): case-controlstudy / J. C. Roujeau // Br. Med. J. – 1999. – Vol. 318. – P. 1591-1594.304. Saple, D. Comparative double-blind, randomized evaluation of efficacy, safetyand toreability of 2-week therapy with sertaconazole nitrate 2% cream vsmiconazole in patients with cutaneous dermatophytosis // D. Saple, A. Surjushe,rao G.
Radhu Rama et al. // Mycoses. – 2009. – P. 2-4.305. Saunte, D. M. Prevalence of toe nail onychomycosis in diabetic patients / D. M.Saunte, J. B. Holgersen, M. Haedersdal et al. // Acta Dermatol. Venerol. – 2006.– Vol. 86. – № 5. – P. 425-8.306. Savin, R. The safety and efficacy of sertaconazole 178 nitrate cream 2% fortinea pedis / R. Savin, J.
Jorizzo // Cutis. – 2006. – Vol. 78. – P. 268-74.307. Schmid-Wendtner, M. H. Topical terbinafine. Reduction of duration of therapyfor tinea pedis / M. H. Schmid-Wendtner, H. Korting // Hautarzt. – 2008. – Vol.59. – № 12. – P. 986-991.308. Sehgal, V. N. Onychomycosis: a 3-year clinicomycologic hospital-based study /V. N. Sehgal, A. K. Aggarwal, G. Srivastava et al. // Skinmed. – 2007.
– Vol. 6.– № 1. – P. 11-17.144309. Sharma, A. Efficacy and tolerability of sertaconazole nitrate 2% cream vs.miconazole in patients with cutaneous dermatophytosis / A. Sharma, D. G. Saple,A. Surjushe, G. R. Rao, M. Kura, S. Ghosh, C. Bolmall, V. Baliga // Mycoses. –2011. – Vol.
54. – № 3. – P. 217-222.310. Shaw, S. W. Onychomycosis: health-related duality of life considerations / S. W.Shaw, V. N. Joish, S. J. Coons / Pharmacoeconomics. – 2002. – Vol. 20. – P.23-36.311. Sigurgeirsson, B. Risk factors associated with onychomycosis / B. Sigurgeirsson,О. Sigurgeirsson // J. Eur. Acad. Dermatol. Venerol. – 2004. – Vol. 18. – № 1. –P. 48-51.312. Stock, I. Antimycotic therapy of Tinea pedis and other foot mycoses / I. Stock //Med. Monatsschr. Pharm. – 2008.
– Vol. 31. – № 7. – P. 247-258.313. Sur, R. Anti-inflammatory activity of sertaconazole nitrate is mediated via activation of a p38-COX-2-PGE2 pathway / R. Sur, J. M. Babad, M. Garay, F. T.,Liebel, M. D. Southall // J. Invest. Dermatol. – 2008. – Vol. 128. – № 2. – P.336-344.314. Susilo, R. Dermatomycoses of the glabrous skin: a double-blind, randomised,181 comparative trial of sertaconazole 2% cream once daily versus vehicle / R.Susilo, H. C. Korting, U.
P. Strauss, Sertaconazole Study Group // Clin. Drug.Investig. – 2003. – Vol. 23. – № 6. – P. 387-94.315. Susilo, R. Rate and extent of percutaneous absorption of sertaconazole nitrateafter topical administration / R. Susilo, H. C. Korting, U. P. Strauss, G. Menke,O. Schuster, A.
Menke // Arzneimittelforschung. – 2005. – Vol. 55. – № 6. – P.338-342.316. Svejgaard, E. L. Onychomycosis in Denmark: prevalence of fungal nail infection in general practice / E. L. Svejgaard, J. Nilsson // Mycoses. – 2004. – Vol.47. – № 3-4. – P. 131-135.317. Svejgaard, E. L. Oral ketokonazole as an alternative to griseofulvin in recalcitrant dermatophyte infections and onychomycosis / E. L.
Svejgaard // ActaDermatol. Venerol. – 1985. – Vol. 65. – P. 143-149.145318. Tan, H. H. Superficial fungal infections seen at the National Skin Centre, Singapore / H. H. Tan // Nippon Ishinkin Gakkai Zasshi. – 2005. – Vol. 46. – № 2. – P.77-80.319. Tarrida, N. Antiinflammatory activity of topically applied sertaconasole nitrate /N. Tarrida, J. Agut, A. Sacristan, J. A. Ortiz // Methods and findings in experimental and clinical pharmacology. – 1996. – Vol. 18. – № 4. – P. 233-4.320. Tasic, S. Etiopathogenesis, clinical picture and diagnosis of onychomycoses / S.Tasic, S.
Stojanovic, M. Poljacki // Med. Pregl. – 2001. – Vol. 54. – № 1-2. – P.45-51.321. Torres, J. Sertaconazole in the treatment of mycoses: from dermatology to gynecology / J. Torres, M. Marquez, F. Camps // International Journal of Gynecology& Obstetrics. – 2000. – Vol. 71. – P.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
